friday novemb market open report third quarter
financi result exhibit slightli beat top bottom
line rais ep growth guidanc due
strong sale key franchis revenu quarter billion
estim billion line consensu billion world-wide humira
revenu billion line estim billion consensu
billion imbruvica revenu record million estim
million consensu million hcv franchis sale million
estim million consensu million note mavyret reach
roughli global market share quarter revenu declin sequenti
due fewer warehous patient certain market non-gaap ep
estim consensu estim complet varianc analysi
expect consensu actual result summar exhibit manag issu
updat guidanc non-gaap ep new
non-gaap ep estim previous within guidanc
compani maintain goal achiev oper margin
compani declar dividend increas per share payabl first quarter
return equiti ttm
biopharmaceut compani major busi franchis autoimmun oncolog virolog
area base north chicago illinoi
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
face strong neg impact eu humira biosimilar entri manag guid double-digit ep
growth updat model estim top-lin growth bottom-lin growth
believ growth contribut imbruvica venclexta franchis well new launch
orilissa upadacitinib risankizumab off-set eu biosimilar impact humira
five-year compound-annual-growth-rate project chang maintain fair valu estim
share continu rout past month larg due macroeconom environ rise interest
rate rotat biopharma sector concern potenti polici chang drug price control reform
rebate/discount practic continu worri surround eu humira biosimilar competit view manag
guid call due entri humira biosimilar europ humira intern sale could declin
estim billion stabil slower declin beyond unit
state expect humira growth driven volum price increas
contribut model lower humira price increas match inflat
januari humira biosimilar entri despit revenu declin ex-u humira continu project top-
bottom-lin compound-annual-growth-rate respect due continu growth exist franchis
new launch maintain fair valu estim share imbruvica sale expect fuel
frontlin cll studi support continu penetr entrench lucr set
venclexta sale acceler label expans well orilissa approv juli treatment
endometriosis-associ pain unit state supplementari new drug applic snda heavi menstrual
bleed associ uterin fibroid track upadacitinib risankizumab pois launch
note two agent demonstr superior humira humira-approv indic
gradual replac humira coincid biosimilar entri sustain growth overal immunolog franchis
note medicin multibillion-dollar peak potenti manag expect launch new
product label expans earli believ help diversifi product mix sustain growth follow
loss exclus compani flagship product
third-quart net revenu billion repres growth year-ago period declin
sequenti top three product humira sale grew year-over-year imbruvica grew year-over-
year hcv franchis sale decreas quarter-over-quart challeng increas price competit
domin humira franchis persever despit competit biosimilar entri eu price pressur howev
humira sale fail reach double-digit year-over-year growth third quarter first time last
quarter exhibit world-wide year-over-year humira growth attribut increas unit
state half volum driven decreas intern exhibit account
abbvi adjust sale quarter imbruvica revenu grew quarter-over-quart includ
increas sale increas intern profit share expect imbruvica continu domin
second-lin chronic lymphocyt leukemia cll set well continu expans frontlin cll margin zone
lymphoma mzl chronic graft-versus-host diseas gvhd expand frontlin cll set lucr
set hcv franchis sale third quarter total million declin second quarter mavyret
alreadi reach hcv market share highest script volum among singular hcv drug
continu forecast peak market share mavyret franchis reach equilibrium gilead hcv
updat estim follow lower full year revenu estim billion
billion result reduct humira intern sale estim billion billion sinc
launch four biosimilar certain intern market mid-octob price discount rang
depend geographi result lower full year humira sale estim billion
also updat estim three new launch increas sale estim orilissa million
million upadacitinib million million risankizumab million
million due robust third-quart imbruvica sale experienc quarter-over-quart growth well recent
frontlin cll approv increas sale estim imbruvica billion billion new
non-gaap ep estim previous within guidanc also increas
ep estim previous due declin intern humira sale off-set strong expect uptak
orilissa upadacitinib risankizumab lower oper expens manag comment compani
continu aim oper margin confid double-digit ep growth
base follow methodolog maintain fair valu estim share updat
pipelin project view exhibit continu trade signific discount peer large-cap
biotech pharma compani exhibit maintain averag price-to-earnings multipl comp group valuat
purpos take averag time non-gaap ep estim time estim time
estim multipl chosen percentil compar biotech pharmaceut
multipl given year use formula arriv fair valu estim share compound-annual-growth-rate
describ continu believ share could gradual garner higher-than-averag multipl go
look numer near-term product launch multibillion-dollar potenti well label expans within
key franchis throughout next month drive top- bottom-lin growth continu support
growth neg eu biosimilar impact humira headlin continu believ
pipelin numer upcom de-risk catalyst across variou therapeut field off-set impact eu humira
biosimilar entri biosimilar entri
regulatori file upadacitinib ra expect fourth quarter follow potenti approv
forecast upadacitinib bring peak sale across numer indic billion billion
attribut sale ra data comprehens phase program upadacitinib rheumatoid arthriti
demonstr highest potenc among market jak inhibitor xeljanz olumi eli
lilli market perform recent top-line filgotinib gilead
galapago glpg appear compar potenc upadacitinib howev safeti remain question
upadacitinib jak inhibitor class whole particularli relat sever cardiovascular cv risk includ
venou thromboembol event vte note recent approv olumi suffer numer
imbal vte event across placebo-control portion phase program ultim result
approv lower two propos dose well limit label popul black box warn
upadacitinib comparator-tr patient show vte associ filgotinib
believ data begin lift prior concern regard associ jak inhibit cv risk combin
demonstr efficaci across spectrum moder sever ra indic believ upadacitinib
pois becom prefer agent among oral jak inhibitor besid ra upadacitinib pivot studi five
indic current approv indic humira
risankizumab continu schedul like approv launch moder sever psoriasi
follow approv indic next five seven year estim sale risankizumab reach
billion second quarter compani submit biolog licens applic bla
risankizumab fda european ema treatment patient moder sever psoriasi base
four phase pivot trial show impress durabl skin clearanc believ risankizumab well
posit approv first indic addit indic evalu next five seven
august orilissa launch treatment endometriosis-associ pain snda treatment
heavi menstrual bleed hmb associ uterin fibroid uf expect follow potenti
approv project orilissa reach blockbust statu bring sale billion across
indic partnership develop orilissa elagolix first-
in-class small-molecul gonadotropin-releas hormon receptor gnrh antagonist safer effect
treatment symptom associ endometriosi uf orilissa treatment endometriosis-associ
pain launch unit state august addit compani pursu hmb-associ uf
second indic orilissa compani announc posit top-line result duplic phase trial
indic earlier year plan submit snda potenti approv follow abbvi
guid estim orilissa sale billion uf endometriosi indic believ
valu asset probabl underappreci continu project billion peak sale indic even
moder penetr
imbruvica continu cornerston hematolog oncolog franchis eight approv
indic sever late-stag develop continu penetr frontlin cll largest
market continu fuel growth maintain peak global sale estim billion expect two
imbruvica combin studi treatment frontlin chronic lymphocyt leukemia cll continu drive
penetr set phase illumin studi imbruvica gazyva significantli improv progression-
free surviv compar gazyva chlorambucil current standard care regimen prioriti review
track approv earli phase ii captiv trial imbruvica venclexta led minim
residu diseas neg patient togeth studi repres addit opportun
penetr frontlin cll market note frontlin mainten set cll constitut largest
treatment popul substanti longer treatment durat deeper penetr market
continu fuel imbruvica growth maintain market-lead posit imbruvica plu rituxan
treatment adult patient waldenstrm macroglobulinemia wm recent approv well late-stag
monotherapi combin studi imbruvica also on-going frontlin pancreat cancer frontlin mantl cell
lymphoma second-lin follicular lymphoma third-lin multipl myeloma could see approv throughout
next three four year model imbruvica achiev billion global peak sale main sourc
revenu imbruvica continu come cll frontlin market share gain entrench well
durat therapi major driver growth
numer label expans venclexta beyond second quarter venclexta gain
second label indic treatment patient relapsed/refractori r/r cll combin rituxan
third quarter fda expand label includ data murano studi venclexta rituxan
achiev minim residu diseas mrd -neg patient versu standard care strong
result venclexta gazyva frontlin cll present fourth quarter approv indic
expect snda venclexta combin hypomethyl agent low-dos cytarabin frontlin
acut myeloid leukemia aml unfit chemotherapi prioriti review breakthrough therapi
design anticip approv indic earli pivot studi also on-going number
addit non-hodgkin lymphoma type includ fl dlbcl wm phase studi multipl myeloma plan
across indic compani project venclexta see five label expans
venclexta also evalu treatment myelodysplast syndrom could support approv around
maintain outperform rate fair valu estim assum price-to-earnings multipl top quartil
among pharma biotech peer project top- bottom-lin compound-annual-growth-rate
beyond humira revenu start declin project top- bottom-lin compound-annual-growth-rate
respect project includ current market product late-stag pipelin candid believ
current earlier-stag asset start contribut growth beyond share remain under-valued
opinion stock trade discount pharma biotech peer even though current repres one
highest growth rate pharma biotech peer group fair valu estim put among top
term price-to-earnings multipl believ growth prospect well strong pipelin deserv premium
risk outperform rate includ earlier-than-project biosimilar entri humira failur
market product fulfil expect failur key pipelin program commerci success polit
risk busi develop risk
humira hcv imbruvica total sg acquir in-process research expense- total oper interest expens net foreign exchang incom expens pre-tax incom tax net non- net intang asset separ mileston acquir acquisit relat intang asset impairment- tax reform repatri tax- impact relat tax law change- tax audit settlement- legal reserves- restructuring- chang fair valu conting transact charit other- non- dividend per common weight averag share outstand compani report william blair inc incom estimatespreadvarianceq/q growthy/i growthcon estimate humira oper net compani report william blair estimatescurr quarterexhibit inc current quarter varianc analysi dollar billion except ep william blair
compani reportsexhibit inc humira world-wide y/i y/i growth compani report william blair estimatesexhibit inc humira y/i growth y/i growtheu y/i growthww y/i record record record record exclud top record abbvi william blair co estimatesexhibit inc estim product revenu william blair
biotechnolog consult last page report disclosur price factset william blair co inc exhibit import disclosur
